Literature DB >> 19419285

Drug delivery systems for the eye.

Victoria R Kearns1, Rachel L Williams.   

Abstract

Topical and systemic administration of drugs to the eye is highly inefficient and there is a need for controlled, sustained release, particularly for conditions that affect the posterior segment. Various nonimplantable and implantable drug delivery devices have been developed. Colloidal carriers may allow targeted drug delivery and afford protection to substances that are sensitive to degradation, particularly RNA/DNA-based treatments. Gene therapy and cell transplantation are also starting to emerge as alternatives to conventional pharmacological treatment. There is the potential to use existing ocular devices to deliver drugs. In order to exploit this opportunity, modifications to drugs and devices, along with clarification of the appropriate drug dose, must be undertaken. This review will describe some of the treatment options for ocular disease and barriers to drug delivery, discuss the design of existing drug delivery systems and highlight some of the research into combining drug delivery with existing ocular medical devices.

Entities:  

Mesh:

Year:  2009        PMID: 19419285     DOI: 10.1586/erd.09.4

Source DB:  PubMed          Journal:  Expert Rev Med Devices        ISSN: 1743-4440            Impact factor:   3.166


  9 in total

Review 1.  Biodegradable implants for sustained drug release in the eye.

Authors:  Susan S Lee; Patrick Hughes; Aron D Ross; Michael R Robinson
Journal:  Pharm Res       Date:  2010-06-10       Impact factor: 4.200

2.  Drug delivery to the posterior segment of the eye for pharmacologic therapy.

Authors:  Shalin S Shah; Lori Vidal Denham; Jasmine R Elison; Partha S Bhattacharjee; Christian Clement; Tashfin Huq; James M Hill
Journal:  Expert Rev Ophthalmol       Date:  2010-02-01

3.  Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy.

Authors:  Jorge L Jacot; David Sherris
Journal:  J Ophthalmol       Date:  2011-10-30       Impact factor: 1.909

4.  Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats.

Authors:  Giselle Foureaux; Juçara Ribeiro Franca; José Carlos Nogueira; Gustavo de Oliveira Fulgêncio; Tatiana Gomes Ribeiro; Rachel Oliveira Castilho; Maria Irene Yoshida; Leonardo Lima Fuscaldi; Simone Odília Antunes Fernandes; Valbert Nascimento Cardoso; Sebastião Cronemberger; André Augusto Gomes Faraco; Anderson José Ferreira
Journal:  PLoS One       Date:  2015-07-23       Impact factor: 3.240

5.  Bimatoprost-loaded ocular inserts as sustained release drug delivery systems for glaucoma treatment: in vitro and in vivo evaluation.

Authors:  Juçara Ribeiro Franca; Giselle Foureaux; Leonardo Lima Fuscaldi; Tatiana Gomes Ribeiro; Lívia Bomfim Rodrigues; Renata Bravo; Rachel Oliveira Castilho; Maria Irene Yoshida; Valbert Nascimento Cardoso; Simone Odília Fernandes; Sebastião Cronemberger; Anderson José Ferreira; André Augusto Gomes Faraco
Journal:  PLoS One       Date:  2014-04-30       Impact factor: 3.240

6.  Safety evaluation of poly(lactic-co-glycolic acid)/poly(lactic-acid) microspheres through intravitreal injection in rabbits.

Authors:  Xianfang Rong; Weien Yuan; Yi Lu; Xiaofen Mo
Journal:  Int J Nanomedicine       Date:  2014-06-24

7.  Endophthalmitis Prophylaxis Using a Single Drop of Thermoresponsive Controlled-Release Microspheres Loaded with Moxifloxacin in a Rabbit Model.

Authors:  Alex Mammen; Eric G Romanowski; Morgan V Fedorchak; Deepinder K Dhaliwal; R M Shanks; Regis P Kowalski
Journal:  Transl Vis Sci Technol       Date:  2016-12-01       Impact factor: 3.283

8.  Novel daily disposable therapeutic contact lenses based on chitosan and regenerated silk fibroin for the ophthalmic delivery of diclofenac sodium.

Authors:  Rachasit Jeencham; Manote Sutheerawattananonda; Saowaluk Rungchang; Waree Tiyaboonchai
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

9.  Controlled Release of Multiple Therapeutics From Silicone Hydrogel Contact Lenses for Post-Cataract/Post-Refractive Surgery and Uveitis Treatment.

Authors:  Stephen A DiPasquale; Biaggio Uricoli; Matthew C DiCerbo; Thea L Brown; Mark E Byrne
Journal:  Transl Vis Sci Technol       Date:  2021-12-01       Impact factor: 3.283

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.